Loading...
XKRX
096530
Market cap1.30bUSD
Oct 08, Last price  
38,150.00KRW
1D
-1.93%
1Q
31.55%
Jan 2017
9.16%
IPO
-1.84%
Name

Seegene Inc

Chart & performance

D1W1MN
XKRX:096530 chart
P/E
35.88
P/S
3.67
EPS
1,063.22
Div yield, %
2.54%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
-15.87%
Revenues
474.23b
+14.48%
51,712,796,63058,992,832,19064,410,877,29065,136,597,35773,693,589,45888,919,576,022102,264,773,396121,953,286,8751,125,215,548,0001,370,833,012,000853,561,091,000367,375,049,000414,251,733,000474,232,000,000
Net income
48.45b
P
9,102,938,4159,572,517,8609,141,388,0906,774,128,6017,122,595,5823,186,975,04510,098,321,71226,672,069,051502,281,109,000536,558,868,000182,138,621,000669,012,000-20,336,849,00048,445,000,000
CFO
149.33b
+74.88%
3,672,940,358-2,893,225,7806,777,155,7004,104,835,65416,557,316,93710,115,432,38814,009,661,69532,643,052,000383,157,254,000334,024,477,000319,008,874,00094,932,061,00085,390,805,000149,333,824,000
Dividend
Sep 29, 2026200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Key people

Internal Auditor · since 2023
Yeong Seok Baek
Assistant Managing Director · since 2022
Jun Yong Ha
Assistant Managing Director · since 2021
Jae Jong Han
Assistant Managing Director · since 2020
Jeong Beom Kim
Assistant Managing Director · since 2024
Hong Ho Kim
Assistant Managing Director · since 2024
Bong Ho Kim
Assistant Managing Director · since 2022
Yun Ji Kim
Assistant Managing Director · since 2022
Jeong Gu Kim
Assistant Managing Director · since 2021
Myeong Yil Kim
Assistant Managing Director · since 2024
Yeong Jo Lee
Assistant Managing Director · since 2022
Jik Yeong Park
Assistant Managing Director · since 2021
Dong Heon Shin
Assistant Managing Director · since 2024
Jin Su Choi
Co-President, Director · since 2024
Dae Hun Lee
Co-President, Co-Chief Executive Officer, Director · since 2024
Gyeong Jun Cheon
Other Non-Executive Director · since 2021
Hyeon Cheol Jung
Non-Executive Independent Director · since 2022
Chang Se Lee
Non-Executive Independent Director · since 2020
IPO date
Sep 10, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT